[ad_1]

CHARLOTTE, N.C.–(Organization WIRE)–cbdMD, Inc., a nationally recognized, hemp derived, customer cannabidiol ( CBD) brand (NYSE American: YCBD), announced nowadays that it has been added to The Cannabis ETF (NYSE: THCX) (“THCX”), which trades on the New York Stock Exchange. THCX seeks to track the Innovation Labs Cannabis Index, which is a portfolio of 36 stocks anticipated to advantage from development of the legal marijuana, CBD and hemp industries.

Martin Sumichrast, cbdMD, Inc. Chairman & Co-CEO, mentioned, “We are incredibly pleased and appreciative of the addition to The Cannabis ETF, right after the newest rebalance. As a hemp derived CBD item, this is a different milestone for our firm that will give us improved exposure to the US investment market place and deliver more momentum in developing on our brand.”

“Being a firm of firsts, in a disruptive market, it is rewarding to be validated by the investment neighborhood. Our addition to The Cannabis ETF will serve as an critical conduit to this neighborhood, in the continued educational efforts of our organization,” mentioned Caryn Dunayer, President & Co-Founder of cbdMD.

Interest in CBD has surged more than current years so a lot so that top cannabis market analyst, The Brightfield Group, expects the market place could hit almost $24 billion by 2022 right after getting valued at $620 million in the United States in 2018. Skilled sports leagues, like the BIG3 and Bellator MMA, let their athletes to use CBD items, particularly cbdMD, for recovery and all round wellness. Nursing residences, classic health-related practitioners, and a lot of non-profit organizations have also embraced CBD.

About cbdMD

cbdMD is a nationally recognized customer cannabidiol ( CBD) brand whose present items consist of CBD tinctures, CBD gummies, CBD topicals, CBD bath bombs, CBD vape oils, and CBD pet items.

Forward-Seeking Statements

This press release consists of particular forward-searching statements that are primarily based upon present expectations and involve particular dangers and uncertainties inside the which means of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-searching statements can be identified by the use of words such as ”should,” ”may,” ”intends,” ”anticipates,” ”believes,” ”estimates,” ”projects,” ”forecasts,” ”expects,” ”plans,” and ”proposes.” These forward-searching statements are not guarantees of future functionality and are topic to dangers, uncertainties, and other elements, some of which are beyond our manage and tricky to predict and could trigger actual outcomes to differ materially from these expressed or forecasted in the forward-searching statements. You are urged to cautiously overview and think about any cautionary statements and other disclosures, such as the statements produced below the heading “Risk Factors” in cbdMD, Inc.’s Annual Report on Type 10-K for the fiscal year ended September 30, 2018, as filed with the Securities and Exchange Commission (the “SEC”) on December 12, 2018, our Quarterly Report on Type 10-Q/A for the period ended December 31, 2018, as filed with the SEC on April 26, 2019, and our Type 10-Q for the period ended June 30, 2019, as filed with the SEC on August 14, 2019, and our other filings with the SEC. All forward-searching statements involve substantial dangers and uncertainties that could trigger actual outcomes to differ materially from these in the forward-searching statements, a lot of of which are typically outdoors the manage of cbdMD, Inc. and are tricky to predict. cbdMD, Inc. does not undertake any duty to update any forward-searching statements except as may well be needed by law.

[ad_2]